SDC1 and Miyoshi myopathy: This highlights the possibility of on-target/off-tumor effects, which was evident in previous clinical trials evaluating an anti-CD138-antibody–drug conjugate in the treatment of MM, as some patients experienced severe mucosal and skin toxicity.